Scientists can have fun and venture out. Dr. Springer’s lecture will provide four ideas on how.
Make discoveries : How do the white blood cells in our blood recognize other cells or leave the bloodstream to fight cancer or infections? The discovery of adhesion molecules, including integrins, using antibodies unveiled the answer.
Unravel the mechanisms: How do integrins transduce chemical signals in cell locomotion and other vital cell functions? The mechanisms are based on integrins which adopt three “conformational states” and transmit forces across cell membranes between the extracellular bases and the cytoskeleton, thus stabilizing the active state of integrins.
Engage in entrepreneurship: New targets for cell-cell recognition and trafficking and new molecular mechanisms have enabled the development of new therapies and the launch of companies to develop them and provide them to patients. This is where the origins of biomedical successes lie, including LeukoSite, Morphic Therapeutic and the Institute for Protein Innovation.
Learn to learn : Scientists are privileged because their field requires them to constantly learn and develop new skills, ideas and even disciplines. Research shows that those who challenge themselves and deliberately practice new skills are more successful than those with a high IQ.
Timothy Springer is an award-winning scientist, eight-time entrepreneur and philanthropist. He is currently the Latham Family Professor of Biological Chemistry and Molecular Pharmacology and Professor of Medicine at Harvard Medical School and Boston Children’s Hospital. Dr. Springer has over 500 publications and 30 patents. He is a member of the National Academy of Sciences and has received the Coley Prize from the Institute for Research on Cancer, the Crafoord Prize and the prestigious Canada International Gairdner Prize, among others. After obtaining his doctorate. in Molecular Biology and Biochemistry from Harvard, Dr Springer began his postgraduate career in the laboratory of Nobel Laureate Cesar Milstein in Cambridge, England. Monoclonal Antibody Research has initiated its extensive and award-winning work on adhesion receptors in the immune system. His discoveries enabled him to launch LeukoSite in 1993, the first of seven successful companies he founded or invested in, including the creator of the COVID vaccine, Moderna Therapeutics. His discovery work and entrepreneurial spirit have led to the development and approval of seven therapies that have treated hundreds of thousands of patients. As a philanthropist, Dr Springer leveraged his entrepreneurial success to launch the Institute for Protein Innovation in 2017, a unique non-profit research institution providing synthetic antibodies and in-depth protein expertise to accelerate biological research. and therapeutic. He has also established Chairs and Chairs at Harvard Medical School, Boston Children’s Hospital, and the University of California. Dr Springer is a former scientist at MBL Whitman and director of the physiology course. He is currently a member of the board of directors.
Friday June 25 at 8 p.m.
at 9:00 p.m.
Cornelia Clapp Auditorium, Laboratory of Marine Biology, https://www.mbl.edu/friday-evening-lectures/
7 MBL Street, Woods Hole, Massachusetts